Condition

Peripheral T Cell Lymphoma clinical trials and research

• 35Clinical trials
• 1NIH research projects
• 11Countries

Newest Peripheral T Cell Lymphoma clinical trials

All recruiting trials (35)

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• XNW5004 with CHOP/CHOEP in Untreated Peripheral T-Cell Lymphoma

  This study tests XNW5004 together with CHOP or CHOEP in adults with newly diagnosed peripheral T-cell lymphoma to see if the combination is safe and active.

  Recruiting Phase 1/2 Evopoint Biosciences Inc. · Shanghai, Shanghai Municipality · NCT07730515

• Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers

  This trial will test whether matching a patient's cancer markers to one of several dual-target CAR-T therapies can work and be safe for adults whose blood cancer has come back or not responded.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523555

• Treatment options for peripheral T‑cell lymphoma after no response to first‑line therapy

  This project will try allogeneic stem cell transplant versus other salvage treatments for adults with peripheral T‑cell lymphoma who did not respond to first‑line chemotherapy.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07470996

• Golidocitinib versus placebo as maintenance treatment for PTCL patients in remission after first-line chemotherapy

  This trial tests whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma from coming back in adults who responded to first‑line chemotherapy but cannot have a stem cell transplant.

  Recruiting Phase 3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07414758

• Cidabenamine plus azacitidine to prevent post-transplant progression in high-risk peripheral T‑cell lymphoma

  This trial will test whether adding cidabenamine to azacitidine after allogeneic stem cell transplant can help prevent progression in adults with high‑risk peripheral T‑cell lymphoma.

  Recruiting Phase 2/3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07389616

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Treatment choices after a complete response to first-line therapy for peripheral T‑cell lymphoma

  This study will test whether autologous stem cell transplant or observation leads to better outcomes for people with peripheral T‑cell lymphoma who are in complete response after first‑line chemotherapy.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07353840

• Ruxolitinib plus pembrolizumab for relapsed or refractory Hodgkin and non-Hodgkin lymphomas

  This trial will try adding ruxolitinib to pembrolizumab to see if it is safe and helps people whose Hodgkin or non-Hodgkin lymphomas have come back or did not respond to prior treatment.

  Recruiting Phase 2 Columbia University · New York, New York · NCT07283822

• Real-world outcomes for peripheral T‑cell lymphoma in Chinese adults

  This project will collect past and new clinical and molecular data to see which treatments and biomarkers work best for adults in China with peripheral T‑cell lymphoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07270861

• Allogeneic versus Autologous Hematopoietic Stem Cell Transplant for Peripheral T‑Cell Lymphoma in Partial Response after First‑line Therapy

  This study will test whether allogeneic or autologous stem cell transplant works better and is safer for adults with peripheral T‑cell lymphoma who have a partial response after first‑line treatment.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07253129

• Golidocitinib versus physician-selected therapy for relapsed/refractory peripheral T‑cell lymphoma (Phase 3 JACKPOT19)

  This Phase 3 test compares golidocitinib with treatments chosen by a doctor to see if it better controls disease in adults with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting at 50 sites Phase 3 Dizal Pharmaceuticals · Hefei, Anhui and 50 other locations · NCT07234162

• Golidocitinib with liposomal mitoxantrone or chidamide for relapsed or refractory peripheral T‑cell lymphoma

  This trial tests whether adding golidocitinib to either liposomal mitoxantrone or chidamide helps adults with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07093710

• Bendamustine plus chidamide and lenalidomide for relapsed or refractory peripheral T‑cell lymphoma

  This study will test whether combining bendamustine, chidamide, and lenalidomide helps adults with relapsed or refractory peripheral T‑cell lymphoma.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07072221

• Evaluating CHT101 for patients with specific blood cancers

  This study is testing a new treatment called CHT101 to see if it can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting Phase 1 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06914037

• Golidocitinib combined with CHOP for treating newly diagnosed peripheral T-cell lymphoma

  This study is testing if a new drug called golidocitinib, when combined with standard chemotherapy, can help people who are newly diagnosed with peripheral T-cell lymphoma.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing · NCT06739265

• Evaluating Golidocitinib for Newly Diagnosed Peripheral T Cell Lymphoma

  This study is testing a new drug called golidocitinib to see if it can help people with newly diagnosed peripheral T cell lymphoma live longer without their cancer getting worse.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06630091

• Using a modified virus to treat patients with T-cell lymphoma

  This study is testing a modified virus combined with immunotherapy to see if it can safely treat patients with different types of T-cell lymphoma.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT06508463

• Combining linperlisib and chidamide for treating peripheral T-cell lymphoma

  This study is testing a new combination of two drugs, linperlisib and chidamide, to see if it can help people with peripheral T-cell lymphoma more than the usual chemotherapy treatment.

  Recruiting at 6 sites Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan and 5 other locations · NCT06421948

• Treatment for patients with aggressive non-Hodgkin's lymphoma

  This study is testing a new combination treatment for people with aggressive non-Hodgkin's lymphoma to see if it helps them feel better and improve their health.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06244368

• Banked C7R-modified allogeneic CD30-targeted CAR T cells for CD30-positive lymphomas

  This will try a donated (banked) C7R.CD30.CAR-EBVST cell infusion to treat people aged 12–75 whose CD30-positive lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT06176690

• Treatment of relapsed or refractory peripheral T-cell lymphoma with Chidamide and Duvalisib

  This study is testing if a new combination of two drugs, Chidamide and Duvalisib, can help people with hard-to-treat peripheral T-cell lymphoma feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06151106

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• New combination therapy for untreated nodal TFH cell lymphoma

  This study is testing a new combination treatment for people with untreated angioimmunoblastic T-cell lymphoma to see if it helps them respond better to therapy.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT05958719

• Genotype-guided treatment for newly diagnosed peripheral T-cell lymphoma

  This study is testing if using genetic information to guide treatment can help people with newly diagnosed peripheral T-cell lymphoma respond better to standard chemotherapy.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05675813

• Transplantation for patients with T-cell lymphoma who have achieved complete response

  This study is testing whether a stem cell transplant can help adults with T-cell lymphoma who have responded well to chemotherapy feel better and live longer compared to just continuing with chemotherapy.

  Recruiting Hospices Civils de Lyon · Amiens and 47 other locations · NCT05444712

• Comparing Lenalidomide with CHOP to CHOP alone for untreated Peripheral T-Cell Lymphoma

  This study is testing if adding lenalidomide to the standard CHOP treatment can help people with untreated peripheral T-cell lymphoma feel better compared to just using CHOP alone.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT04922567

• Combining Sintilimab and Chidamide for treating Peripheral T-cell Lymphoma

  This study is testing a new treatment combining Sintilimab and Chidamide to see if it can help people with relapsed or hard-to-treat peripheral T-cell lymphoma feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT04512534

• Evaluating a new oral medication for certain types of cancer

  This study is testing a new oral medication for people with certain types of lymphoma and advanced solid tumors to see how safe it is and if it helps them.

  Recruiting at 21 sites Phase 1/2 Haihe Biopharma Co., Ltd. · Phoenix, Arizona and 24 other locations · NCT04390737

• Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma

  This study is testing a new treatment called ST-001 to see if it can help people with relapsed T-cell non-Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting at 10 sites Phase 1 SciTech Development, Inc. · Scottsdale, Arizona and 9 other locations · NCT04234048

• Treatment for relapsed or refractory CD30+ T cell lymphoma using modified T cells

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat CD30+ T cell lymphoma.

  Recruiting at 2 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina and 1 other locations · NCT04083495

• Evaluating CCS1477 for blood cancers

  This study is testing a new drug called CCS1477 to see if it can help people with certain blood cancers who haven't responded to other treatments.

  Recruiting at 34 sites Phase 1/2 CellCentric Ltd. · Atlanta, Georgia and 38 other locations · NCT04068597

• Testing a microdevice for drug screening in skin lesions of T-cell lymphoma

  This study is testing a small device that delivers cancer drugs directly into skin lesions to see if it helps people with cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04045470

• International registry for patients with newly diagnosed peripheral T-cell lymphoma

  This study is collecting information from people who have just been diagnosed with peripheral T-cell lymphoma to better understand the disease and improve treatment options.

  Recruiting at 3 sites Associazione Angela Serra per la ricerca sul cancro · Stanford, California and 5 other locations · NCT03964480

• Chemoimmunotherapy and stem cell transplant for NK T-cell leukemia and lymphoma

  This study is testing two different treatment combinations for people with advanced NK-cell leukemia and lymphoma to see which one works better before they receive a stem cell transplant.

  Recruiting at 6 sites Early Phase 1 New York Medical College · Birmingham, Alabama and 5 other locations · NCT03719105

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Targeting specific mutations in T cell lymphoma for treatment

  This study is looking for better ways to treat peripheral T cell lymphoma, an aggressive cancer, by using new technology and existing medications to target specific genetic changes in the disease, with the hope of finding more effective treatments for patients like you.

  NIH research Texas A&m University Health Science Ctr · College Station, United States · NIH-10873914

Related topics

Quick answers

How many Peripheral T Cell Lymphoma clinical trials are recruiting right now?

35, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in China (21 trials), United States (14 trials), France (2 trials), Taiwan (1 trial), Thailand (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 9, Phase 1/2: 8, Phase 1: 4, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →